Chippenham-based speciality pharmaceutical group Alliance Pharma has spent £1.5m acquiring two skin treatment brands to add to its growing portfolio of established dermatology medicines.
Acne treatment Quinoderm and Ceanel, a shampoo treatment for scalp psoriasis, which were bought from Ferndale Pharmaceuticals, had total sales of around £600,000 in the year to September 30, 2011.
Quinoderm complements Alliance Pharma’s Rizuderm (isotretinoin) treatment for severe acne which it acquired last September. The deal was the group’s third acquisition on 2011.
Alliance Pharma chief executive John Dawson, said the group expected the two new brands to be earnings enhancing in 2012, and added: “We continue to evaluate further opportunities to broaden our product portfolio.”
The deal was funded by drawing a loan from a £20m revolving credit facility put in place in November 2010 to fund acquisitions. So far Alliance has used £6.5m of the facility.
